Monitor for the appointment of a permanent CEO and any associated strategic shifts. The interim appointment of a former CEO suggests continuity, but the lack of financial data makes this a non-event for near-term trading.
Price Chart
Executive Summary
Purple Biotech announced the appointment of former CEO and current board member Isaac Israel as Interim CEO, effective October 5, 2026, replacing Gil Efron who transitions to Executive Director of Corporate Development. This is a routine leadership transition with no material financial or operational data disclosed.
Key Facts
- Isaac Israel appointed Interim CEO effective October 5, 2026, pending permanent CEO appointment.
- Israel previously served as CEO from October 2012 to July 2022 and as Acting CEO from March to August 2023.
- Gil Efron steps down as CEO, transitions to Executive Director, Head of Corporate Development, effective October 5, 2026.
- Efron remains on the Board of Directors.
- No financial figures, guidance, or operational metrics were disclosed in the filing.
Financial Impact
No financial impact disclosed.
Risk Factors
- Prolonged interim CEO period could signal difficulty in finding a permanent replacement.
- No material financial or operational updates provided; stock may be driven by broader biotech sector sentiment.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106852 |
| Document: 0001213900-26-106852-index-headers.html | 0001213900-26-106852 |
| Document: 0001213900-26-106852-index.html | 0001213900-26-106852 |
| Document: 0001213900-26-106852.txt | 0001213900-26-106852 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 today | Press Release | $0.9300 | awaiting T+60 | awaiting T+60 | $1.09 (+17.20%) |
Oct 5, 2026 24d ago | 6-K | $1.47 | awaiting T+60 | awaiting T+60 | $1.09 (−25.85%) |
Sep 9, 2026 7w ago | 6-K | $1.74 | awaiting T+60 | awaiting T+60 | $1.09 (−37.36%) |
Sep 2, 2026 8w ago | 6-K | $1.98 | awaiting T+60 | awaiting T+60 | $1.09 (−44.95%) |
Aug 10, 2026 11w ago | 6-K | $1.55 | awaiting T+60 | awaiting T+60 | $1.09 (−29.68%) |
Aug 7, 2026 11w ago | 6-K | $1.43 | awaiting T+60 | awaiting T+60 | $1.09 (−23.78%) |
May 15, 2026 23w ago | Press Release | $3.94 $1.55 | ▼ −60.66% | ▼ −65.18% | $1.09 (−72.34%) |
Apr 27, 2026 26w ago | 6-K | $4.59 $1.33 | ▼ −71.02% | ▼ −75.80% | $1.09 (−76.25%) |
Apr 23, 2026 27w ago | 6-K | $4.55 $1.45 | ▼ −68.13% | ▼ −73.15% | $1.09 (−76.04%) |
Mar 13, 2026 32w ago | Press Release | $4.10 $2.92 | ▼ −28.78% | ▼ −40.40% | $1.09 (−73.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers